5 Specialty Pharma Stocks Nomura Is Picking To Weather The Storm

  • Shibani Malhotra of Nomura is expecting the specialty pharmaceutical and generics "merger frenzy" will continue into 2016.
  • Malhotra argued that companies with access to capital are now "more likely" to pursue deals, be it either friendly or hostile.
  • However, Malhotra cautioned that investor reaction to M&A is "not as uniformly positive" today as it was in 2014.
  • Shibani Malhotra, Nomura's specialty pharmaceuticals and generics industry analyst, initiated coverage of the sector with five Buy-rated recommendations.

    According to Malhotra, the "merger frenzy" seen in the sector is expected to continue into 2016. The analyst noted that the industry faces an "increasingly challenging" macroeconomic environment, characterized by patent expiration, pricing pressures and customer consolidations.

    As such, management teams and boards of directors face "immense" pressure to focus their efforts on "optimal capital allocation."

    The Role Of 'Optimal Capital Allocation'

    Malhotra continued that companies with access to capital are now "more likely" to go on the acquisition hunt and acquire their peers either through friendly or hostile deals.

    However, investor sentiment has shifted as of late and investors are now "more carefully assessing individual deals" and are only beginning to focus on execution and results from deals completed in the past 18 months.

    Related Link: 2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out

    Buy Companies With Favorable Risk-To-Reward Profiles

    Malhotra initiated coverage of the following five names with Buy ratings given their positively skewed risk-to-reward profiles and low-risk value drivers that are not currently reflected in their stock.

    • Allergan PLC AGN's management is likely to use capital from the recent sale of its generics business to "generate shareholder value." In addition, the "strength and sustainability" of its underlying business remains "underappreciated."
    • Valeant Pharmaceuticals Intl Inc VRX's "solid execution" will be a "key driver of value," while M&A activity will "play a role" in further upside.
    • Pacira Pharmaceuticals Inc PCRX's market opportunity for its Exparel suggests "significant growth potential."
    • Endo International plc - Ordinary Shares ENDP investors "appear to be missing" the true value of the recent Par acquisition, which will become "clearer" when the deal closes.
    • RedHill Biopharma Ltd – ADR RDHL currently has three phase III candidates with a total market opportunity of $10.3 billion. Accordingly, the stock represents an "attractive" long-term investment.
    Image Credit: Public Domain
    Posted In: ExparelGenericsNomurapharmaceutical companiesPharmaceutical M&AShibani MalhotraSpecialty PharmaceuticalAnalyst ColorBiotechLong IdeasHealth CareTop StoriesAnalyst RatingsTrading IdeasGeneral

    Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

    All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

    Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

    Rate collection and criteria: Click here for more information on rate collection and criteria.